Is a Generic Diovan for You?

Health and Healthcare

Published: January 5, 2015 4:25 pm

Last Updated: April 27, 2020 11:51 pm

Many investors have to worry about the so-called patent cliff in pharmaceutical companies. Generic launches are often priced into most analyst estimates, but these generic launches are always important to look at when they come in the blockbuster drug category with more than $1 billion in annual sales. So what are investors, and patients, supposed to think when Mylan Inc. (NASDAQ: MYL) is launching a generic version of Diovan, a Novartis A.G. (NYSE: NVS) brand product.

Diovan is an important drug because it is indicated for the treatment of hypertension to lower blood pressure. Its annual sales also exceeded $2 billion. This may sound like a first, but Ranbaxy of India received FDA approval in 2014 to market its generic version of Diovan.

Apart from this generic version of Diovan, Mylan has 284 abbreviated new drug applications (ANDAs) pending FDA approval, which represent $109.2 billion in annual brand sales, according to IMS Health. Out of the pending ANDAs, 44 are potential first-to-file opportunities.

Mylan is a global pharmaceutical company that offers a growing portfolio of over 1,300 generic pharmaceuticals and several brand medications. The company also offers a range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. Currently, Mylan markets its products in roughly 140 countries and territories with a workforce of over 25,000 people.

Shares of Mylan were down 1% at $55.76 in the last two hours of trading Monday. The stock has a consensus analyst price target of $59.75 and a 52-week trading range of $41.97 to $59.60.

Shares of Novartis did not seem to react to Mylan’s announcement and are up less than 1% at $92.45 in afternoon trading. Something else to note is that Novartis has a market cap of $223 billion, compared to Mylan’s market cap of $21 billion. Novartis has a consensus analyst price target of $100.87 and a 52-week trading range of $77.90 to $96.97.

ALSO READ: America’s Most (and Least) Healthy States

It’s Your Money, Your Future—Own It (sponsor)

Are you ahead, or behind on retirement? For families with more than $500,000 saved for retirement, finding a financial advisor who puts your interest first can be the difference, and today it’s easier than ever. SmartAsset’s free tool matches you with up to three fiduciary financial advisors who serve your area in minutes. Each advisor has been carefully vetted and must act in your best interests. Start your search now.

If you’ve saved and built a substantial nest egg for you and your family, don’t delay; get started right here and help your retirement dreams become a retirement reality.